Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 400 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $59.54, for a total value of $23,816.00. Following the completion of the transaction, the vice president now owns 83,478 shares in the company, valued at approximately $4,970,280.12. This trade represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Meredith Cook also recently made the following trade(s):

• On Monday, January 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $53.92, for a total value of $21,568.00.

ANI Pharmaceuticals Trading Down 0.4 %

Shares of ANI Pharmaceuticals stock opened at $59.73 on Friday. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $70.81. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The company has a market capitalization of $1.26 billion, a P/E ratio of -108.60 and a beta of 0.74. The company has a fifty day moving average of $57.05 and a 200 day moving average of $58.24.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. US Bancorp DE raised its stake in ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after purchasing an additional 531 shares during the period. KBC Group NV grew its holdings in ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after buying an additional 600 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in ANI Pharmaceuticals during the 4th quarter valued at approximately $166,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after buying an additional 579 shares during the last quarter. Finally, Rafferty Asset Management LLC purchased a new position in shares of ANI Pharmaceuticals in the fourth quarter worth $200,000. Institutional investors own 76.05% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ANIP shares. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Finally, StockNews.com upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 5th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.